More Than 35,000 Annual Procedures Expand CGuard Prime’s Target Market
Key Facts
InspireMD is moving toward launching the CGuard Prime system for use in transcarotid artery revascularization procedures in the United States, after the U.S. Food and Drug Administration approved the system on November 9, 2026. The company estimated that the approval gives it access to more than 35,000 additional procedures annually in its U.S. target market and doubles the platform’s total addressable market there. In its filing, it said U.S. sales of the system intended for these procedures are expected to begin soon, during the fourth quarter of 2026. The timing remains the company’s stated estimate, and there is no independent confirmation that the first commercial procedure using the system has taken place. The move puts commercial execution at the forefront of the product’s progress following completion of the regulatory approval process.
The approval covers the 80-centimeter version of CGuard Prime, which the company said in its November 16 financial filing it had in commercial inventory ready for launch. The FDA recorded its decision approving the supplement to the marketing authorization application on November 9. The company said the product is intended for use with a specified embolic protection system, as stated in the device labeling. Use is also limited to high-risk patients for carotid endarterectomy who require revascularization. These conditions define the patient group and method of use covered by the approval, while the anticipated start of sales remains a subsequent indicator of the product’s market entry.
According to the company, the approval was based on the pivotal C-GUARDIANS 2 study, a U.S. multicenter study involving 50 patients at 11 research sites. The study evaluated the system in transcarotid revascularization procedures, using the ENROUTE neuroprotection system, in patients at high surgical risk. InspireMD said the results showed 100% acute device success. It added that there were no deaths, strokes, myocardial infarctions or stent thromboses within 30 days of the procedure. These results present the company’s reported findings on device performance in the study and during the specified observation period, without changing the scope of the patient group for whom the approval permits its use.
The platform’s commercial context also includes another version previously launched in the United States: the company disclosed that commercial sales of the 135-centimeter version of CGuard Prime began in July 2025. That earlier launch is separate from the 80-centimeter version approved for transcarotid revascularization procedures. In May 2026, the company announced a voluntary U.S. recall of the 135-centimeter version after the delivery system’s technical success rate did not meet its expectations. It said the action was limited to the delivery system and did not include the implanted stent. By September 30, 2026, it reported that affected products had been returned and customer credits issued, with a revenue reduction of approximately $734,000 and an inventory impairment provision of approximately $612,000 related to the recall.
In its financial filing, InspireMD said its resources were insufficient to fund operations for at least 12 months based on its reported financial position. The company disclosed that it closed an offering on November 16, 2026, generating gross proceeds of approximately $37.5 million before discounts and expenses. The financing follows disclosure of the financial impact associated with returns of recalled products, while the anticipated launch phase coincides with the company’s preparations to market the new version. The company also set December 2026 as the expected date for submitting an approval supplement to the FDA concerning modifications to the delivery system for the CGuard Prime version intended for carotid angioplasty procedures. It said relaunch of that version could take place in the first half of 2027.
The company said approval for use in transcarotid revascularization procedures marks a milestone that enables the latest-generation implant to enter the market for these procedures. At the Vascular and Endovascular Issues, Techniques and Horizons (VEITH) Symposium scheduled in New York from November 17 to 21, 2026, InspireMD announced scientific presentations covering results from the C-GUARDIANS 2 study and an update on the C-GUARDIANS 3 study. According to its announcement, the program includes 3-year follow-up data for 621 asymptomatic patients. The presentations come in the week the company announced it had commercial inventory of the 80-centimeter version and was targeting the start of sales in the fourth quarter. The stated sales start date, alongside the scientific presentations, remains among the key specified developments following the approval decision.